Table 1.
Plasma cfDNA | |||||||||
---|---|---|---|---|---|---|---|---|---|
Patient | Sex | Agea | VM Type | Location | Variant | Tissue VAF (%)b | Plasma volume (mL)c | VAF (%)b | Droplets (Var/WT) |
LR16-173 | F | 15 | AVM | Ear |
MAP2K1 p.K57N (c.171G>T) |
8.2 | 3.3 0.9 0.5 |
0.4 NEG NEG |
21/4823 1/2151 0/1107 |
LR17-049 | F | 18 | AVM | Face, temple |
MAP2K1 p.Q56P (c.167A>C) |
5.9 | 0.9 0.5 |
1.6 2.1 |
9/531 47/2096 |
LR13-356 | M | 19 | AVM | Face, buccal |
MAP2K1 p.K57N (c.171G>T) |
7.2 | 0.9 | NEG | 2/1793 |
LR17-050 | M | 1.4 | AVM | Anterior scalp |
BRAF p.V600E (c.1799T>A) |
21.2 | 0.4 | NEG | 1/810 |
LR17-205 | M | 13 | AVM | Face, forehead |
MAP2K1 p.K57N (c.171G>T) |
5.2 | 0.6 1.3 |
NEG NEG | 0/38305 0/1437 |
LR17-207 | M | 18 | AVM | Face, supraorbital |
MAP2K1 p.K57N (c.171G>T) |
1.0 | 3.0 | NEG | 0/2131 |
LR17-208 | F | 11 | AVM | Hand |
MAP2K1 p.K57N (c.171G>C) |
13.7 | 1.3 0.6 0.9 |
NEG NEG NEG | 0/974 0/764 0/1337 |
LR18-541 | M | 8 | AVM | Ear |
MAP2K1 p.K57N (c.171G>T) |
6.1 | 0.3 0.5 |
NEG NEG | 0/83 1/304 |
LR18-542 | M | 4 | VeM | Face, buccal |
TEK p.L914F (c.2740C>T) |
3.3 | 0.8 | 1.6 | 21/1329 |
LR16-024 | M | 8 | VeM | Tongue |
TEK p.L914F (c.2740C>T) |
7.5 | 4.0 | NEG | 1/1673 |
LR17-197 | M | 3 | VeM | Face, buccal |
TEK p.L914F (c.2740C>T) |
8.0 | 2.3 0.7 |
NEG NEG |
0/1900 0/44 |
Abbreviations: AVM – arteriovenous malformation, NEG – no variant detected, VAF – variant allele fraction, Var – variant, VM – vascular malformation, VeM – venous malformation, WT – wild-type.
Age at earliest plasma collection in years.
VAF calculated using droplet concentrations and only reported for samples in which sample variant concentration was statistically different from WT cfDNA control variant concentration based on 95% total error confidence intervals.
Samples taken at separate time points when multiple volumes listed excepting LR18–541 who had two plasma samples from the same day.